All peptides discussed in this guide are sold by Webber for in vitro research purposes only.
Introduction
The incretin peptide landscape has evolved rapidly from single-receptor GLP-1 agonists to dual and now triple agonists. Understanding the pharmacological differences between GLP-1 receptor agonists (semaglutide), GLP-1/GIP dual agonists (tirzepatide), and GLP-1/GIP/glucagon triple agonists (GLP-3 (Ret)) is essential for Canadian researchers designing metabolic studies.
This guide compares these three classes mechanistically, pharmacologically, and in terms of published research data.
GLP-1 Receptor Agonists (Single Agonist)
Representative Peptide: Semaglutide
Mechanism: GLP-1R agonist — mimics endogenous GLP-1, binding to and activating the glucagon-like peptide-1 receptor on pancreatic beta cells, GI tract neurons, and CNS appetite-regulating centers.
Research highlights:
- Insulin secretion — Glucose-dependent insulinotropic effect; enhances first-phase insulin response
- Glucagon suppression — Reduces glucagon secretion in hyperglycemic states
- Gastric emptying delay — Slows gastric motility, contributing to satiety
- Appetite regulation — Acts on hypothalamic POMC neurons and NPY/AgRP pathways
- Cardiovascular benefits — SUSTAIN-6 and SELECT trials demonstrated significant MACE reduction
Note: Webber currently does not carry semaglutide. See our tirzepatide guide and GLP-3 (Ret) comparison for alternatives we offer.
GLP-1/GIP Dual Agonists
Representative Peptide: Tirzepatide
Mechanism: Dual GLP-1R/GIPR agonist — activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, creating synergistic metabolic effects.
Research highlights:
- Superior glycemic control — SURPASS programme showed -2.0% to -2.4% HbA1c reduction vs -1.5% to -1.8% for semaglutide in head-to-head comparisons
- Weight reduction — 15–22% body weight reduction in phase 3 trials, exceeding GLP-1-only agonists
- GIP-specific effects — Enhances adipose tissue lipid metabolism and improves insulin sensitivity through additive GIPR activation
- Dual incretin synergy — GIP potentiates GLP-1’s insulinotropic effect while adding complementary metabolic pathways
See our complete tirzepatide guide for protocol details.
GLP-1/GIP/Glucagon Triple Agonists
Representative Peptide: GLP-3 (Ret) (LY3437943)
Mechanism: Triple agonist — simultaneously activates GLP-1R, GIPR, and GCGR (glucagon receptor). The addition of glucagon receptor agonism creates a third metabolic axis.
Research highlights:
- Maximum weight reduction — Phase 2 trial showed up to -24.2% body weight reduction at 12mg (highest dose), exceeding both semaglutide and tirzepatide results
- Glucagon-mediated thermogenesis — GCGR activation increases energy expenditure through hepatic and brown adipose tissue pathways
- Lipid metabolism — Reduces hepatic steatosis and improves lipid panels beyond dual agonist effects
- Blood pressure — Greater systolic blood pressure reductions than dual agonists in comparative models
- Dose-dependent selectivity — At lower doses, GLP-1R effects dominate; at higher doses, GIPR and GCGR contributions become more prominent
See our GLP-3 (Ret) overview and the full comparison guide for detailed analysis.
Buy GLP-3 (Ret) (GLP-3) for research →
Comparative Summary Table
| Feature | Semaglutide (GLP-1) | Tirzepatide (GLP-1/GIP) | GLP-3 (Ret) (GLP-1/GIP/Glucagon) |
|———|———————|————————–|———————————–|
| Receptors activated | GLP-1R | GLP-1R, GIPR | GLP-1R, GIPR, GCGR |
| Weight reduction (max) | ~15% | ~22% | ~24% |
| HbA1c reduction | -1.5 to -1.8% | -2.0 to -2.4% | Phase 3 ongoing |
| Energy expenditure increase | Modest | Moderate | Significant (glucagon) |
| GI side effect profile | Moderate | Moderate-High | Moderate-High |
| Lipid effects | Moderate | Good | Excellent |
| Availability at Webber | No | No | Yes |
Frequently Asked Questions
Why add glucagon receptor activation if it raises blood sugar?
Glucagon increases energy expenditure through thermogenesis (brown adipose tissue activation) and lipid oxidation. The GLP-1R and GIPR components override glucagon’s hyperglycemic effects, yielding net improved glycemia while adding the metabolic benefits of increased energy expenditure.
Is GLP-3 (Ret) better than tirzepatide for research?
“Better” depends on the research question. Tirzepatide has more published clinical data. GLP-3 (Ret) shows superior hormone balance efficacy in phase 2 but lacks phase 3 completion. For labs studying maximum metabolic activation, GLP-3 (Ret) is the more potent tool. For labs needing the largest evidence base, tirzepatide may be preferred.
Can these peptides be studied together?
Combinatorial studies are possible but require careful dose titration. Most published protocols use single agents. See our peptide blends methodology guide for research design considerations.
Related Research Guides
- Hormone Balance & Metabolic Peptides Guide
- Tirzepatide Complete Guide
- GLP-3 (Ret) vs Semaglutide vs Tirzepatide Comparison
- GLP-3 (Ret): The Triple G Peptide
- AOD9604 Research Guide
Disclaimer: All peptides discussed in this guide are provided by Webber for in vitro research purposes only. Not intended for human consumption, diagnosis, or treatment. Tirzepatide and semaglutide references are for academic comparison only.